Table 1.
Relationship between EIF3B expression and clinicopathological features in GC patients using IHC analysis
| Parameter | EIF3B expression | χ2 | Pa | |
|---|---|---|---|---|
| Low n (%) |
High n (%) |
|||
| Gender | 0.759 | 0.384 | ||
| Male | 20(29.0) | 49(71.0) | ||
| Female | 5(20.0) | 20(80.0) | ||
| Age (y) | 0.128 | 0.721 | ||
| ≤60 | 13(28.3) | 33(71.7) | ||
| >60 | 12(25.0) | 36(75.0) | ||
| Tumor location | 0.490 | 0.484 | ||
| 1/3 Upper +1/3 Middle | 11(23.4) | 36(76.6) | ||
| 1/3 Lower | 14(29.8) | 33(70.2) | ||
| Tumor size (cm) | 1.869 | 0.172 | ||
| ≤5 | 17(32.1) | 36(67.9) | ||
| >5 | 8(19.5) | 33(80.5) | ||
| Histologic type | 0.033 | 0.856 | ||
| Adenocarcinoma | 20(27.0) | 54(73.0) | ||
| Non-adenocarcinoma | 5(25.0) | 15(75.0) | ||
| Differentiation degree | 0.469 | 0.494 | ||
| Well + middle | 11(30.6) | 25(69.4) | ||
| Poor | 14(24.1) | 44(75.9) | ||
| Lauren | 0.257 | 0.613 | ||
| Intestinal | 17(28.3) | 43(71.7) | ||
| Diffuse + mixed | 8(23.5) | 26(76.5) | ||
| Depth of invasion | 13.789 | 0.000 | ||
| T1–2 | 9(75.0) | 3(25.0) | ||
| T3–4 | 16(19.5) | 66(80.5) | ||
| Vascular invasion | 2.124 | 0.145 | ||
| Absent | 14(34.1) | 27(65.9) | ||
| Present | 11(20.8) | 42(79.2) | ||
| Lymph node metastasis | 21.281 | 0.000b | ||
| N0 | 15(62.5) | 9(37.5) | ||
| N1 | 10(14.3) | 60(85.7) | ||
| Distant metastasis | 0.103 | 0.748 | ||
| M0 | 24(27.6) | 63(72.4) | ||
| M1 | 1(14.3) | 6(85.7) | ||
| TNM stage | 21.040 | 0.000b,c | ||
| Ⅰ | 9(90.0) | 1(10.0) | ||
| Ⅱ | 5(23.8) | 16(76.2) | ||
| Ⅲ | 10(17.9) | 46(82.1) | ||
| Ⅳ | 1(14.3) | 6(85.7) | ||
| PCNA expression | 6.797 | 0.009 | ||
| Low | 17(39.5) | 26(60.5) | ||
| High | 8(15.7) | 43(84.3) | ||
Notes: aChi-square test, bP<0.0001, cKruskal–Wallis Test. Statistically significant (P<0.05) shown in bold.